NCT00044551View on ClinicalTrials.gov

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

February 28, 2002

Study Completion Date

July 31, 2003

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

Taxane (Cytotoxic, BAY59-8862)

Daily 1 h infusion every 3 weeks

Trial Locations (23)

10595

Valhalla

12200

Berlin

33140

Miami Beach

38120

Memphis

44195

Cleveland

53226

Milwaukee

54500

Vandœuvre-lès-Nancy

60637

Chicago

69495

Pierre-Bénite

75151

Paris

79106

Freiburg im Breisgau

98195

Seattle

71130-4228

Shreveport

08903-2681

New Brunswick

11235-3518

Brooklyn

11030-3876

Manhasset

13210-2399

Syracuse

10467-2490

The Bronx

T6G 1Z2

Edmonton

1081 HV

Amsterdam

Unknown

Groene Hilledijk

CB2 0QQ

Cambridge

ME16 9QQ

Maidstone

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY